RxDoctor Payments Data

Dale Helman, MD

Neurology · Salinas, CANPI 1407926009

Payments from drug & device makers

$20,093in general payments, 2019–2025

Across 951 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Biogen$2K
  • UCB, Inc.$1K
  • Neurocrine Biosciences, Inc.$802
  • Pfizer$773
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$19,86599%
  • Education$2281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)140$2,528
Teva Pharmaceuticals USA, Inc.82$2,132
Biogen103$1,991
UCB, Inc.38$1,090
Neurocrine Biosciences, Inc.33$802
Pfizer46$773
Bristol Myers Squibb36$687
Adamas Pharmaceuticals, Inc.31$652
Eisai Inc.33$632
Lilly USA, LLC27$627
Kyowa Kirin, Inc.33$536
Acorda Therapeutics, Inc25$496
Livanova USA, Inc.29$488
Lundbeck LLC17$451
Johnson & Johnson(2 entities)18$367
Genentech USA, Inc.15$354
Amgen(2 entities)14$336
Novartis16$308
Banner Life Sciences, LLC14$268
Supernus Pharmaceuticals, Inc.12$247
EMD Serono, Inc.10$242
SK Life Science, Inc.9$232
Biohaven Pharmaceutical Holding Company Ltd.11$226
Otsuka America Pharmaceutical, Inc.10$224
Amneal Pharmaceuticals LLC9$206
CSL Behring6$199
Impel Pharmaceuticals Inc.13$186
MDD US Operations, LLC8$180
Alnylam Pharmaceuticals Inc.7$161
Biohaven Pharmaceuticals, Inc.9$160
Grifols USA, LLC6$151
AstraZeneca7$143
Avion Pharmaceuticals4$139
Argenx US, Inc.5$132
Upsher-smith Laboratories LLC7$129
Sanofi6$127
Octapharma USA, Inc.4$126
Abbott5$114
Neuronetics, Inc.3$90
Sanofi-aventis U.S. LLC5$88
Scilex Pharmaceuticals Inc.4$84
Averitas Pharma Inc.3$83
Vanda Pharmaceuticals Inc.3$83
Merz Pharmaceuticals, LLC2$73
Boston Scientific3$59
Axsome Therapeutics, Inc.2$52
GE HealthCare2$49
Electronic Waveform Lab, Inc.2$47
Arbor Pharmaceuticals, Inc.2$46
Hospira, Inc.2$45
Merck2$44
Acadia Pharmaceuticals Inc2$44
Promius Pharma LLC2$39
Mallinckrodt Hospital Products Inc.1$35
Catalyst Pharmaceuticals, Inc.1$27
Avanir Pharmaceuticals, Inc.1$27
TG Therapeutics, Inc.1$27
Neurelis, Inc.1$26
Life Molecular Imaging Ltd1$25
Vertex1$24

How this compares

$20,093 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$477,419
Medicare patients
749
Services billed
3,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate22$145,539
Nurtec OdtRimegepant Sulfate42$101,644
NourianzIstradefylline36$66,704
CopaxoneGlatiramer Acetate11$65,428
UbrelvyUbrogepant31$42,019
Rivastigmine120$23,996
Memantine Hcl ErMemantine Hcl152$21,530
QuliptaAtogepant14$16,702
Aimovig AutoinjectorErenumab-Aooe16$13,622
Sumatriptan Succinate88$9,976
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen362$6,793
Donepezil Hcl303$6,477
TegretolCarbamazepine11$5,953
Carbidopa-LevodopaCarbidopa/Levodopa198$5,138
Gabapentin315$4,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$1,991$145,53922 claims
PfizerNurtec Odt$773$101,64442 claims
Kyowa Kirin, Inc.Nourianz$536$66,70436 claims
Teva Pharmaceuticals USA, Inc.Copaxone$2,132$65,42811 claims
AbbVieUbrelvy, Qulipta$2,528$58,72145 claims
Upsher-smith Laboratories LLCTopiramate$129$57152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →